Immuron to sell Travelan® in South Korea

THE ROADHOUSE PHARMACY: Immuron Limited (ASX: IMC), manufacturer of Travelan®, has entered into an agreement with DB Pharm Korea for the sale of Travelan® in South Korea.

Under the agreement DB Pharm Korea is granted exclusive rights to market, distribute, and sell Travelan® in South Korea.

Travelan® is clinically-proven to prevent the main cause of travellers’ diarrhoea, with 90 per cent efficacy.

Immuron referenced the World Tourism Organisation, in saying diarrheal illness is by far the most common health impairment associated with international tourism in terms of frequency and economic impact.

The agreement requires DB Pharm Korea to comply with specified annual minimum order obligations and it is also required to attain regulatory approval from the Korean Food and Drug Administration (KFDA) for the sale of Travelan® as an over-the-counter drug in South Korea.

Immuron said an application to the KFDA is currently being prepared with approval expected within approximately 12 months.

DB Pharm intends to market Travelan® nationwide through pharmacies, targeting both overseas travellers, especially to south-east Asian countries including China, and local patients suffering from diarrhoea particularly during the Korean summer season.

DB Pharm is a product-driven company with expertise in therapeutics and hospital market with a network of sub-distributors throughout South Korea.

“As we continue to expand the global Travelan® franchise, we look forward to a mutually beneficial working relationship with DB Pharm,” Immuron chief executive officer Amos Meltzer said in the company’s announcement to the ustralian Securities Exchange.

“DB Pharm has a proven record of successfully working with its partners over a long period of time which is reassuring to us.”

Website: www.immuron.com